Published 9 February 2009, doi:10.1136/bmj.b499
Cite this as: BMJ 2009;338:b499

News

NICE recommends kidney cancer drug it previously rejected on cost grounds

Susan Mayor

1 London

The first 150 words of the full text of this article appear below.

The UK National Institute for Health and Clinical Excellence (NICE) is recommending the use of sunitinib as a first line treatment for advanced kidney cancer, in draft guidance issued this week. The guidance comes after NICE applied new arrangements for assessing the cost effectiveness of drugs for people who are terminally ill, overturning its previous ruling that the drug did not offer the NHS value for money.

The latest draft guidance recommends sunitinib, an oral tyrosine kinase inhibitor, as a first line treatment option in advanced or metastatic renal cell carcinoma in patients who are suitable for immunotherapy and who are fit enough.

However, the guidance does not recommend the use of three other drugs—bevacizumab, sorafenib, and temsirolimus—for first line treatment for these patients. Furthermore, the two drugs that are also licensed for second line treatment, sorafenib and sunitinib, are not recommended by NICE for second line treatment.

The previous . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

NICE lifts cost limit on drugs to improve access to end of life treatments
Zosia Kmietowicz
BMJ 2009 338: b3. [Extract] [Full Text]

Professors call for review of way cancer drugs in NHS are rationed
Zosia Kmietowicz
BMJ 2008 337: a1450. [Extract] [Full Text]

Access jobs at BMJ Careers
Whats new online at Student BMJ